Phase 2
Completed N=97
Onsite Buprenorphine Treatment at Syringe Exchange Programs
Opiate Addiction
Source: ClinicalTrials.gov NCT03150173 ↗
Enrolled (actual)
97
Serious AEs
3.1%
Results posted
Jan 2025
Primary outcomePrimary: Buprenorphine Engagement — 19; 19 Participants — p=0.94
Summary
This trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community health center for buprenorphine treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Buprenorphine Engagement |
19; 19 | 0.94 |
| SECONDARY Treatment Retention |
2; 6 | 0.148 |
| SECONDARY HIV Risk Behaviors |
5; 4 | 0.6132 |
| SECONDARY Buprenorphine Diversion |
8; 2 | .051 |
| SECONDARY Incremental Cost-effectiveness Ratio (ICER) |
-805067 | — |
| SECONDARY Quality-adjusted Life-years (QALYs) Gained |
0.20; 0.17 | 0.10 |
| SECONDARY Mean Difference in Total Costs |
2702.43; 26853.97 | < 0.01 sig |
| SECONDARY Time to First Buprenorphine Prescription |
3.0; 14.0 | 0.011 sig |
| SECONDARY Number/Percentage of Participants Who Received Any Buprenorphine Prescription |
36; 29 | 0.098 |
| SECONDARY Total Time Prescribed Buprenorphine |
46.7; 56.6 | 0.256 |
Eligibility Criteria
Inclusion Criteria
- age ≥ 18 years
- opioid use disorder
- interest in buprenorphine treatment
- motivation for opioid use disorder treatment
- willingness to accept community health center referral
- syringe exchange participant
Exclusion Criteria
- receiving opioid agonist treatment in the past 30 days (confirmed by New York Prescription Drug Monitoring Program);
- inability to provide informed consent
- unstable mental illness (e.g., suicidality, psychosis, etc.)
- severe alcohol use disorder or benzodiazepine use disorder by the Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) criteria
- hypersensitivity to buprenorphine or naloxone.
- pregnancy (confirmed via urine testing)
Data sourced from ClinicalTrials.gov (NCT03150173). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.